The EPS beat is modest and the wider loss is expected for a clinical-stage biotech. The real catalysts are the OPERA-01 top-line data (fall 2026) and OP-3136 ASCO data (late May/June). Monitor these events for binary outcomes that could move the stock 30-50%.
OLMA drugs
OLMA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $13.97entry
- T+1 · 6mo ago −2.79%α −3.37% · $13.58
- T+5 · 6mo ago −7.66%α −7.74% · $12.90
- T+20 · 5mo ago −29.71%α −27.98% · $9.82
- T+60 · 3mo ago −15.53%α −19.92% · $11.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Olema Oncology reported Q1 2026 EPS of -$0.52, a 7.2% beat vs consensus of -$0.54, but net loss widened to $53.1M from $30.4M a year ago due to increased R&D spending on late-stage trials. The stock is driven by upcoming catalysts: top-line Phase 3 OPERA-01 data expected fall 2026 and initial Phase 1 OP-3136 data at ASCO this month.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.52 vs consensus -$0.54 (7.2% beat)
- Net loss $53.1M vs $30.4M YoY, driven by higher R&D spend
- Cash position $505.3M as of March 31, 2026
- Top-line Phase 3 OPERA-01 data expected fall 2026
- Initial Phase 1 OP-3136 data to be presented at ASCO May/June 2026
- Phase 3 OPERA-02 enrollment continuing
Financial Impact
Net loss increased 75% YoY to $53.1M; cash burn rate ~$53M/quarter
Risk Factors
- Phase 3 OPERA-01 failure would be a severe negative catalyst
- Cash burn rate implies ~2.5 years of runway; potential dilution risk
- OP-3136 Phase 1 safety/efficacy data could disappoint
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292656 |
Track record
20 reports on OLMA
1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $7.27 Now $7.36 +1.24% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
- Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
- Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers